Hamish Alan Cameron
Director/Miembro de la Junta en Artios Pharma Ltd. .
Perfil
Hamish Alan Cameron currently works at Artios Pharma Ltd., as Director, SV Health Investors LLP, as Venture Partner, and The Royal College of Physicians, as Member.
Dr. Cameron also formerly worked at MedImmune Ltd., as Chief Executive Officer from 2006 to 2008, X2-Pharma GmbH, as Chief Executive Officer, Cell Medica Switzerland AG, as Chief Executive Officer & Director, TopiVert Ltd., as Chairman & Interim Chief Executive Officer, Affinium Pharmaceuticals Ltd., as Director, Faculty of Pharmaceutical Medicine, as Director, VHsquared Ltd., as Director, AstraZeneca PLC, as Senior Vice President-Medical Research, Janssen-Cilag Ltd., as Principal, and ESBATech AG, as Chief Commercial Officer.
Dr. Cameron received his undergraduate degree and doctorate degree from the University of London.
Cargos activos de Hamish Alan Cameron
Empresas | Cargo | Inicio |
---|---|---|
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Inversor de Capital Privado | 02/01/2008 |
The Royal College of Physicians | Corporate Officer/Principal | - |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Hamish Alan Cameron.
Empresas | Cargo | Fin |
---|---|---|
TopiVert Ltd.
TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Director Ejecutivo | 31/12/2020 |
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Director Ejecutivo | 01/01/2008 |
Janssen-Cilag Ltd.
Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Janssen-Cilag Ltd. provides pharmaceutical products and services. It offers medicines that can treat serious health conditions such as schizophrenia, epilepsy, multiple myeloma, and human immunodeficiency virus/acquired immunodeficiency syndrome. The firm's other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology, and anaemia. The company was founded on October 19, 1971 and is headquartered in High Wycombe, the United Kingdom. | Corporate Officer/Principal | - |
ASTRAZENECA PLC | Corporate Officer/Principal | - |
Faculty of Pharmaceutical Medicine | Director/Miembro de la Junta | - |
Formación de Hamish Alan Cameron.
University of London | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ASTRAZENECA PLC | Health Technology |
Empresas privadas | 11 |
---|---|
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
Janssen-Cilag Ltd.
Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Janssen-Cilag Ltd. provides pharmaceutical products and services. It offers medicines that can treat serious health conditions such as schizophrenia, epilepsy, multiple myeloma, and human immunodeficiency virus/acquired immunodeficiency syndrome. The firm's other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology, and anaemia. The company was founded on October 19, 1971 and is headquartered in High Wycombe, the United Kingdom. | Health Technology |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
Affinium Pharmaceuticals Ltd.
Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |
Faculty of Pharmaceutical Medicine | |
X2-Pharma GmbH
X2-Pharma GmbH Pharmaceuticals: MajorHealth Technology X2-Pharma GmbH develops pharmaceutical products for the treatment of inflammatory diseases. It is a biopharmaceutical company that offers small molecule pharmaceuticals for the treatment of inflammatory diseases. The company is headquartered in Heidelberg, Germany. | Health Technology |
Cell Medica Switzerland AG
Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Health Technology |
TopiVert Ltd.
TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
VHsquared Ltd.
VHsquared Ltd. BiotechnologyHealth Technology VHsquared Ltd. develops antibody domain products. It operates as a development stage biologics company which develops a portfolio of orally delivered antibody domain products for gastro intestinal health. The company's novel antibody platform will provide a portfolio of new and innovative functional food products to target gastrointestinal infectious and immune mediated diseases. VHsquared leverages the existing research and expertise at the Sanger Institute to facilitate the development of products that function at the gastro intestinal mucosal interface harnessing recent technological developments, including analysis of the micro biota and advances in mucosal immunology. VHsquared was founded in 2010 by William Roderick Justin Richards, Janet Rosemary Robinson, James Scott Crowe, and Gordon Dougan and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Hamish Alan Cameron